

## **Companion Diagnostics: Technologies and Markets**

Market Research Report | 2023-05-05 | 286 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

### **Report description:**

Description

Report Scope:

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints and challenges in the market. The report also features market projections to 2027 and market ranking for key market players. It also covers the competitive environment and regulatory scenario. The report details the companion diagnostics market share based on product and Service, type of test, technology and application. The market is segmented based on product and Service into instruments, consumables and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, others, and services. Based on the application, the companion diagnostics market is segmented into cancer, neurologic disorders, cardiovascular disease, infectious disease and others. The report includes company profiles of the key players in the companion diagnostics market with detailed information about each company's business segments, financials, product portfolios and recent developments. The report also covers the impact of the COVID-19 pandemic on this market.

By geography, the market has been segregated into North America, Europe, Asia-Pacific and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year and 2027 as the forecast year.

Report Includes:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 43 data tables and 60 additional tables
- Detailed overview and an up-to-date analysis of the global market for companion diagnostics (CDx)
- Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for the global CDx market in USD million values, and corresponding market share analysis by product and service, technology, application, type of test, and region
- Identification of the viable technology drivers and barriers through a holistic review of various platform technologies and their potential applications in the development of new CDx products
- Discussion of feasible market opportunities for companion diagnostics products via identification of high-growth applications in different therapeutic areas, with a focus on the biggest and fastest-expanding markets for diseases
- Updated information on recent market developments and clinical trials, as well as the leading companies engaged in research and development (R&D) and products in the companion diagnostics reagent pipeline with SWOT analyses
- Review of the patents and patent applications on companion diagnostics and deep dive of recent patent publications related to CDx products and technologies
- Insight into the recent industry structure of companion diagnostics, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis
- Descriptive company profiles of the leading global players, including Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Foundation Medicine Inc., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific Inc.

## Executive Summary

### Summary:

The global market for companion diagnostics was valued at \$REDACTED billion in 2021. The market is forecast to grow from \$REDACTED billion in 2022 at a compound annual growth rate (CAGR) of REDACTED% to reach about \$REDACTED billion by the end of 2027. This report segments the global market by product and service, type of test, technology, application, and region.

### Reasons for Doing This Study:

Precision medicine or personalized medicine is the future of healthcare. PM is currently the most advanced in oncology, but it has broader applications beyond oncology in fields such as neurology and cardiovascular diseases. Companion diagnostics (CDx) has emerged with the advent of personalized medicine.

Companion diagnostics is developed parallel to a new drug via the drug-diagnostic co-development model. The field has expanded from a few oncology drugs with companion diagnostics to involve multiple therapeutic areas, and the number of combinations has increased substantially over the years. The rapidly surging interest of the medical community and pharmaceutical companies in personalized medicine will create demand for companion diagnostics.

This BCC Research report, "Companion Diagnostics: Technologies and Markets," will provide a detailed analysis of the key factors governing the growth of the companion diagnostics industry, including strategic insights and recommendations for those players looking to expand their markets.

### **Table of Contents:**

- Table of Contents
- Chapter 1 Introduction
  - 1.1 Overview
  - 1.2 Study Goals and Objectives

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.3 Reasons for Doing This Study
- 1.4 What's New in This Update?
- 1.5 Scope of Report
- 1.6 Information Sources
- 1.7 Research Methodology
- 1.8 Geographic Breakdown
- 1.9 Analyst's Credentials
- 1.10 BCC Custom Research
- 1.11 Related BCC Research Reports
- Chapter 2 Summary and Highlights
- 2.1 Highlights of the Market for Companion Diagnostics (CDx)
- Chapter 3 Market and Technology Background
- 3.1 Introduction
- 3.2 Personalized Medicine and Biomarkers
- 3.2.1 Predictive Biomarkers
- 3.3 Companion Diagnostics and Complementary Diagnostics
- 3.3.1 Companion Diagnostics Development
- 3.3.2 CDx Stakeholders
- 3.3.3 Technologies Used in CDx
- 3.3.4 Applications of CDx
- 3.3.5 Regulatory Aspects of CDx
- Chapter 4 Global Market for Companion Diagnostics by Product and Service
- 4.1 Market Overview
- 4.2 Market Share and Forecast
- 4.2.1 Instruments
- 4.2.2 Consumables
- 4.2.3 Services
- Chapter 5 Global Market for Companion Diagnostics by Type of Test
- 5.1 Market Overview
- 5.2 Market Share and Forecast
- 5.2.1 LDT-CDx
- 5.2.2 Commercial CDx
- Chapter 6 Global Market for Companion Diagnostics by Technology
- 6.1 Market Overview
- 6.2 Market Share and Forecast
- 6.2.1 Immunohistochemistry
- 6.2.2 In Situ Hybridization
- 6.2.3 Polymerase Chain Reaction
- 6.2.4 Next-Generation Sequencing
- 6.2.5 Genotyping
- 6.2.6 Others
- 6.2.7 Services
- Chapter 7 Global Market for Companion Diagnostics by Application
- 7.1 Market Overview
- 7.2 Market Share and Forecast
- 7.2.1 Cancer
- 7.2.2 Market for the Application of CDx in Cancer by Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.2.3 Neurologic Disorders
- 7.2.4 Cardiovascular Disease
- 7.2.5 Infectious Disease
- 7.2.6 Other Diseases
- Chapter 8 Global Market for Companion Diagnostics by Region
  - 8.1 North America
    - 8.1.1 U.S.
    - 8.1.2 Canada
  - 8.2 Europe
    - 8.2.1 Germany
    - 8.2.2 U.K.
    - 8.2.3 France
    - 8.2.4 Italy
    - 8.2.5 Rest of Europe
  - 8.3 Asia-Pacific
    - 8.3.1 China
    - 8.3.2 Japan
    - 8.3.3 India
    - 8.3.4 Rest of Asia-Pacific
  - 8.4 Rest of the World
- Chapter 9 Industry Structure
  - 9.1 Overview
  - 9.2 Stakeholders in Companion Diagnostics
  - 9.3 Driving Trends in Companion Diagnostics
  - 9.4 Business Models of Companion Diagnostics
  - 9.5 Grants and Funding in Companion Diagnostics
  - 9.6 Collaborations and Partnerships
  - 9.7 Mergers and Acquisitions
    - 9.7.1 Market Share Analysis
  - 9.8 Leading Market Players in Companion Diagnostics Market, by Technology
    - 9.8.1 Leading Market Players in IHC Market
    - 9.8.2 Leading Market Players in ISH Market
    - 9.8.3 Leading Market Players in PCR Market
    - 9.8.4 Leading Market Players in NGS Market
    - 9.8.5 Leading Market Players in Genotyping Market
    - 9.8.6 Leading Market Players in Others (Tropism, MRI) CDx Market
- Chapter 10 Patent Review
  - 10.1 Introduction
  - 10.2 Patents on Companion Diagnostics Market
  - 10.3 Patent Analysis
    - 10.3.1 Patents by Year
    - 10.3.2 Patents by Top Applicant
    - 10.3.3 Patents by Top Owner
    - 10.3.4 Patents by Jurisdiction
- Chapter 11 Clinical Trials Analysis
  - 11.1 Introduction
  - 11.2 Clinical Trials and CDx

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

11.3 Clinical Trials Analysis  
11.3.1 Clinical Trials Analysis, by Type of Study  
11.3.2 Clinical Trials Analysis, by Status  
11.3.3 Clinical Trials Analysis, by Phase  
11.3.4 Clinical Trials Analysis, by Region  
11.3.5 Clinical Trials Analysis, by Application  
11.3.6 Companies with Companion Diagnostics in Clinical Trials  
Chapter 12 Analysis of Market Opportunities

12.1 Introduction  
12.2 Market Dynamics  
12.2.1 Strengths  
12.2.2 Challenges  
12.2.3 Opportunities  
12.2.4 Threats  
12.3 Impact of the COVID-19 Pandemic

Chapter 13 Company Profiles

ABBOTT

ADAPTIVE BIOTECHNOLOGIES CORP.

AGILENT TECHNOLOGIES INC.

AMOY DIAGNOSTICS CO., LTD.

ALMAC GROUP LTD.

ARUP LABORATORIES

AUTOGENOMICS INC. (ACQUIRED BY PRESCIENT MEDICINE)

BIOCARTIS

BIODESIX INC.

BIOFLUIDICA

BIOMERIEUX SA

BIO-TECHNE

CERBA RESEARCH

CIRCULOGENE

DANAHER

DIASORIN S.P.A.

EXACT SCIENCES CORP.

F. HOFFMANN-LA ROCHE LTD.

GUARDANT HEALTH INC.

HOLOGIC INC.

ICON PLC

ILLUMINA INC.

INVIVOSCRIBE INC.

MAZE THERAPEUTICS

MYRIAD GENETICS INC.

NEOGENOMICS LABORATORIES

QIAGEN

QUEST DIAGNOSTICS INC.

RESONANCE HEALTH LTD.

SIEMENS HEALTHINEERS AG

SPARTAN BIOSCIENCE INC.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

SYSMEX CORP.  
THERMO FISHER SCIENTIFIC INC.  
TRIMGEN CORP.  
VELA DIAGNOSTICS INC.  
Chapter 14 Appendix: Acronyms

**Companion Diagnostics: Technologies and Markets**

Market Research Report | 2023-05-05 | 286 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

